Exodus Point Capital Management, LP Affimed N.V. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $75,382 - $102,188	-13,607 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $105,862 - $155,119	13,607 New	13,607 $116,000
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $214,297 - $354,930	-41,855 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $74,749 - $166,294	23,655 Added 129.97%	41,855 $244,000
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $59,331 - $86,086	18,200 New	18,200 $62,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $562M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.